Physician profile
Ross E Kerns
NPI 1023018728
$34,284.86
in general payments reported to CMS, 2019-2025
69 companies · $3,684 in 2025
The $3,684 reported for 2025 was more than what 78% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12K · 2020: $3,082 · 2021: $4,888 · 2022: $3,397 · 2023: $3,261 · 2024: $3,781 · 2025: $3,684.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $11K · Education: $49.93.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,675.47 |
| Education | $49.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $9,303.15 | 2019-2025 | Reblozyl, Pomalyst, Pomalyst |
| E.R. Squibb & Sons, L.L.C. | $2,501.67 | 2019-2025 | Opdivo, Breyanzi, Pomalyst |
| Amgen INC. | $1,668.88 | 2019-2023 | Xgeva, Vectibix, Nplate |
| Astrazeneca Pharmaceuticals Lp | $1,483.43 | 2019-2025 | Tagrisso, Imfinzi, Calquence |
| Genentech USA, INC. | $1,452.08 | 2019-2025 | Phesgo, Tecentriq, Perjeta |
| Seagen INC. | $1,406.85 | 2019-2023 | Tukysa, Padcev, Adcetris |
| Genzyme Corporation | $1,118.75 | 2019-2025 | |
| Janssen Biotech, INC. | $1,095.38 | 2019-2025 | Erleada, Akeega, Tecvayli |
| Incyte Corporation | $1,035.89 | 2019-2025 | Jakafi, Monjuvi, Zynyz |
| Novartis Pharmaceuticals Corporation | $988.98 | 2019-2025 | |
| Abbvie INC. | $935.74 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $905.80 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Glaxosmithkline, LLC. | $903.19 | 2020-2025 | Ojjaara, Jemperli, Blenrep |
| Pfizer INC. | $900.85 | 2019-2025 | |
| Astellas Pharma US INC | $628.22 | 2019-2025 | Vyloy, Padcev, Xtandi |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ross Kerns listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.